Topic: commercial manufacturing
Novo Nordisk’s site in Kalundborg, Denmark, but will be expanded to produce even more.
AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.
Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.
Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.
Esteve has a deal to buy a specialty drug manufacturing plant in Germany after selling a its generics business and plant in Spain.
Rising Pharmaceuticals pleads to price fixing, and a pilot-scale lyophilization facility is being made available for pilot projects.
Teva Pharmaceuticals is having issues with its API plant in Italy serious enough that it has had to stop production.
In this webinar, AstraZeneca and Catalent Biologics experts will share a case study on a 30-day commercial launch plan for a product into new markets and why this approach was important for patients.
Merck & Co. won’t be able to fully meet global demand for HPV vaccine Gardasil until after 2023 when it completes two manufacturing plants.
Mylan recalls generic Xanax and Lonza expands cell therapy operations in Singapore while Glenmark is delivered an FDA warning letter.